EUVIMEDSkopri EUVIMED
Crossref

The evolution of tyrosine‐kinase‐targeted cancer therapies

Mike Leahy

Future Prescriber · 2006

DOI: 10.1002/fps.14 ↗

At a glance

Journal article in Future Prescriber, 2006. Written by Mike Leahy.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.

Cite

APA

Leahy, M. (2006). The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. https://doi.org/10.1002/fps.14

Vancouver

Leahy M. The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. 2006. doi:10.1002/fps.14

BibTeX
@article{Leahy2006,
  author = {Leahy, Mike},
  title = {The evolution of tyrosine‐kinase‐targeted cancer therapies},
  journal = {Future Prescriber},
  year = {2006},
  doi = {10.1002/fps.14}
}
Start for free →